Hemo Organic Ltd (524590)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 17 அக். 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 17 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Hemo Organic Ltd reported Q2 FY27 results on 17 Oct 2026: revenue ₹1.4 Cr, and net profit ₹0.0 Cr (against a loss a year earlier); the operating margin was 0.4%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹1.4 | — | — |
| செயல்பாட்டு லாபம் | ₹0.0 | நஷ்டத்திலிருந்து | நஷ்டத்திலிருந்து |
| நிகர லாபம் | ₹0.0 | நஷ்டத்திலிருந்து | நஷ்டத்திலிருந்து |
| EPS (₹) | 0.01 | நஷ்டத்திலிருந்து | நஷ்டத்திலிருந்து |
| செயல்பாட்டு லாப வரம்பு | 0.4% | — | — |
- திருப்பம்: ஓராண்டுக்கு முன் நஷ்டத்திற்கு மாறாக லாபம்
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹0.0 கோடி லாபத்தில், ₹0.0 கோடி (100%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Hemo Organic Limited reported the conversion of 34,00,000 convertible equity share warrants into equity shares on September 25, 2026. The company had initially received 25% (Rs 1.06 cr) in February 2026 and the remaining 75% (Rs 3.19 cr) during the quarter, bringing the total funds raised to Rs 4.25 cr. This fundraise represents approximately 61% of the company's Rs 7 cr market capitalization and is primarily earmarked for working capital requirements (Rs 3.19 cr) and general corporate purposes (Rs 1.06 cr). The company confirmed zero deviation in the utilization of the proceeds.
- Converted 34,00,000 warrants into an equivalent number of equity shares on September 25, 2026
- Total issue size of Rs 4.25 cr at an issue price of Rs 12.50 per share (including Rs 2.50 premium)
- Received balance 75% consideration amounting to Rs 3,18,75,000 during the quarter
- Proceeds allocated: Rs 318.75 lakh for working capital and Rs 106.25 lakh for general corporate purposes with zero deviation
Hemo Organic Limited held its board meeting on October 17, 2026, approving the un-audited standalone financial results for the quarter and half year ended September 30, 2026. The meeting commenced at 04:00 p.m. and concluded at 06:30 p.m. The disclosure covers the approval alongside the statutory auditor's Limited Review Report, though specific financial metrics were not included in this text extract. The company operates at a micro-cap size of Rs 7 Cr market cap with TTM revenue of Rs 1 Cr.
- Board meeting commenced at 04:00 p.m. and concluded at 06:30 p.m. on 17th October, 2026
- Approved un-audited standalone financial results for the quarter and half year ended 30th September, 2026
- Limited Review Report from statutory auditors was taken on record
Hemo Organic's Board has approved a massive increase in its Authorised Share Capital from ₹13.45 crore to ₹125.00 crore, subject to shareholder approval. The company is altering its Main Objects to pivot into diamond trading, manufacturing, and real estate development. A proposed fundraise was deferred to a subsequent board meeting. The company also appointed Ms. Pratibha Sharma as Company Secretary and Compliance Officer effective October 3, 2026.
- Authorised Share Capital increased from ₹13.45 crore (1.345 crore shares) to ₹125.00 crore (12.5 crore shares of ₹10 each)
- Proposed authorised capital of ₹125 crore represents nearly 18x the current market cap of ₹7 crore
- Complete pivot of business objects to diamond trading/cutting/polishing and real estate development
- Board deferred proposed fundraising to an upcoming meeting
- Appointed Ms. Pratibha Sharma as Company Secretary & Compliance Officer w.e.f. October 3, 2026
Hemo Organic Ltd has scheduled a Board meeting on October 3, 2026, to consider a proposal for raising funds via equity shares, convertible securities, or warrants through modes like preferential allotment, QIP, or rights issue. The company has a micro-cap valuation of Rs 7 crore with weak financials, including zero revenue in Q1 FY27 (Jun 2026) and a net worth of Rs 0 crore against Rs 3 crore in debt. Additionally, the trading window has been closed from September 29, 2026, until 48 hours after Q2 FY27 results.
- Board meeting scheduled for Saturday, October 3, 2026 to consider fundraising
- Fundraising instruments include Equity Shares, Convertible Securities, or Convertible Warrants
- Proposed routes include preferential allotment, QIP, rights issue, or private placement
- Trading window closed from September 29, 2026 until 48 hours post Q2 FY27 results declaration
Hemo Organic Limited approved the allotment of 34,00,000 equity shares upon the conversion of warrants at Rs 12.50 per share. The company received the remaining 75% consideration amounting to Rs 3.19 crore from two non-promoter entities, Vacro Enterprises and Qmin Realities. This doubles the company's equity base from 34,65,900 shares to 68,65,900 shares, resulting in a ~49.5% dilution. The total inflow of Rs 3.19 crore represents approximately 45% of the company's existing market capitalization of Rs 7 crore.
- 34,00,000 equity shares allotted upon conversion of equal number of warrants at Rs 12.50 per share
- Raised Rs 3,18,75,000 (Rs 3.19 cr) on receipt of 75% balance consideration
- Vacro Enterprises and Qmin Realities each hold a 24.76% post-issue equity stake
- Paid-up equity share capital expanded from 34,65,900 shares to 68,65,900 shares
Promoters Dineshbhai Shanabhai Patel and Sonalben Dineshbhai Patel have entered into Share Purchase Agreements (SPAs) dated September 22, 2026, to sell 5,67,958 equity shares. This represents 16.38% of the company's equity capital, effectively offloading virtually all of the promoter group's reported 16.85% holding. The shares are being sold via off-market transactions to four buyers, including Ketanaben Jasani, Heema Makadia, V9BIZ Business Solution LLP, and Jasani Family Trust. The listed entity is not a party to the agreement, and no board seats or special rights are granted under the terms.
- Promoters to sell 5,67,958 equity shares, representing 16.38% of existing equity share capital
- Sale accounts for 8.27% of fully diluted share capital assuming full warrant conversion
- Ketana Ben Jasani, Heema Makadia, and V9BIZ Business Solution LLP each acquiring 1,55,986 shares (4.50% each)
- Jasani Family Trust acquiring an aggregate of 1,00,000 shares (2.88% total from both promoters)
- SPAs executed on September 22, 2026, with consideration mutually agreed and no special/management rights granted
Hemo Organic Ltd has scheduled a Board of Directors meeting on September 23, 2026, to evaluate and approve fundraising proposals. The company is exploring multiple routes including equity shares, convertible securities/warrants, preferential allotment, rights issue, or QIP. Given the micro-cap market size of Rs 7 crore and TTM revenue of Rs 1 crore, any significant capital injection could heavily dilute or reshape the equity base. Trading window restrictions are in place from September 19, 2026, until 48 hours post-meeting.
- Board meeting scheduled on September 23, 2026, to consider fund raising
- Fundraise options include equity shares, convertible warrants, preferential allotment, rights issue, or QIP
- Trading window closed from closing hours of September 19, 2026, until 48 hours post-meeting
- Company currently holds a market cap of approximately Rs 7 Cr with TTM revenue of Rs 1 Cr
Hemo Organic Limited has announced the closure of its Register of Members and Share Transfer Books from September 1, 2026 to September 8, 2026, for its 34th Annual General Meeting. The cut-off date to determine shareholders eligible to receive the AGM notice was August 7, 2026. The cut-off date to participate in e-voting has been fixed as September 1, 2026. This is a procedural corporate governance filing with no direct financial impact.
- Book closure period scheduled from September 1, 2026 to September 8, 2026 (both days inclusive)
- Cut-off date for participating in e-voting set as September 1, 2026
- Notice cut-off date for dispatch was August 7, 2026
- Filing pertains to the convening of the 34th Annual General Meeting
Hemo Organic Ltd has released its Annual Report for FY 2025-26 and scheduled its 34th Annual General Meeting (AGM) for September 8, 2026. The company reported a revenue of ‡0.93 crore and a net loss of ‡0.78 crore for the fiscal year. A key agenda item is the appointment of M/s. V S S B & Associates as the new Statutory Auditors for a five-year term, replacing the retiring auditors. The company continues to face financial stress with a reported net worth of ‡0 crore and a high debt-to-equity ratio of 21.08.
- 34th Annual General Meeting scheduled for September 8, 2026, at 3:00 P.M. via video conferencing.
- Record date for determining member voting eligibility is set for September 1, 2026.
- Proposed appointment of M/s. V S S B & Associates as Statutory Auditors for a 5-year term starting from this AGM.
- FY26 annual revenue reported at ‡0.93 crore with an operating margin of -53.76%.
- Promoter holding remains stagnant and low at 16.85% as of the latest June 2026 filing.
Hemo Organic Ltd has approved the appointment of M/s. V S S B & Associates as its Statutory Auditor for a five-year term, spanning from the 34th AGM to the 39th AGM. This appointment follows the expiration of the tenure of the previous auditor, M/s. M A A K & Associates. The company, which currently has a market capitalization of just Rs 7 Cr and a net worth of Rs 0 Cr, will seek shareholder approval for this change at the Annual General Meeting (AGM) scheduled for September 8, 2026. This is a routine regulatory requirement under the Companies Act, 2013.
- Appointment of M/s. V S S B & Associates for a 5-year consecutive term starting from the 34th AGM.
- Previous auditor M/s. M A A K & Associates' tenure expires at the conclusion of the 34th AGM.
- 34th Annual General Meeting (AGM) scheduled for September 8, 2026, via Video Conferencing.
- Board meeting held on August 13, 2026, concluded at 6:00 P.M. to approve these changes.
- Jitendra Parmar & Associates appointed as Scrutinizer for the e-voting process.
Hemo Organic Ltd has announced the retirement of its statutory auditor, M/s. M A A K & Associates, effective from the conclusion of the 34th Annual General Meeting (AGM) on September 8, 2026. The auditor has completed the maximum permissible tenure under the Companies Act, 2013, and is therefore ineligible for re-appointment. This is a routine regulatory transition for the micro-cap company, which currently has a market capitalization of Rs 7 Cr and a negative net worth. Investors should note the company's fragile financial state, with TTM losses of Rs 1 Cr and a high debt-to-equity ratio of 21.08.
- Statutory Auditor M/s. M A A K & Associates to retire at the conclusion of the 34th AGM on September 8, 2026
- The auditor was originally appointed at the 25th AGM held on September 30, 2017
- The firm completed two terms, with the second term starting from the 30th AGM on September 24, 2022
- Company reports a TTM revenue of Rs 1 Cr against a debt of Rs 3 Cr
- The retirement is mandatory under the provisions of the Companies Act, 2013
Hemo Organic Ltd has appointed M/s. Jitendra Parmar & Associates as Secretarial Auditor for FY 2025-26 and M/s. Umesh Khese & Co. as Internal Auditor for FY 2026-27. These appointments, approved on August 4, 2026, are mandatory compliance steps under the Companies Act, 2013. The company is in a precarious financial state with a net worth of Rs 0 Cr and debt of Rs 3 Cr. With FY26 revenue at just Rs 0.93 Cr, maintaining regulatory compliance is essential for its continued listing despite ongoing losses.
- Secretarial Auditor appointed for FY 2025-26 to ensure legal compliance
- Internal Auditor appointed for FY 2026-27 with over 30 years of professional practice
- Board meeting conducted on August 4, 2026, lasting exactly 1 hour from 5:00 PM to 6:00 PM
- Secretarial Auditor firm brings over 9 years of corporate legal experience
Hemo Organic Ltd has approved its un-audited financial results for the quarter ended June 30, 2026, following a board meeting on July 15, 2026. The meeting lasted 75 minutes, concluding at 5:15 p.m. The filing confirms the submission of the Limited Review Report as per SEBI regulations. While the cover letter does not detail specific revenue or profit figures, it marks the formal reporting of the company's performance for the first quarter of the fiscal year.
- Board meeting held on July 15, 2026, lasting from 04:00 p.m. to 05:15 p.m.
- Approval of un-audited financial results for the quarter ended June 30, 2026.
- Submission includes the mandatory Limited Review Report under Regulation 33 of SEBI LODR.
- Stock has demonstrated a significant 131.5% price return over the last 3 months.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
